The antibiotic erythromycin did not affect micronucleus frequency in human PHA-stimulated lymphocytes by Grujičić D. et al.
INTRODUCTION
Erythromycin is a macrolide antibiotic that is used 
to treat various infections, particularly in patients 
allergic  to  penicillin  (Czeizel  et  al.,  1999).  This 
medicament  is  essentially  bacteriostatic,  that  is  it 
inhibits protein synthesis by binding reversibly to 
the 50 S subunits of sensitive microorganisms, but 
in high concentrations erythromycin is bactericidal 
against very susceptible organisms (Kapusnik-Uner 
et al., 1996). The antibiotic is concentrated in the 
liver and is excreted as the active form in the bile. It 
is most often administered orally or intravenously. 
The usual daily dose for adults ranges from 1 to 2 g, 
while for children the usual dose is 30-50 mg/kg per 
day (Sweetman, 2002).
Because erythromycin has a broad spectrum of 
activity, it is used in the treatment of a wide variety 
of infections. This antibiotic is most effective in vitro 
against anaerobic gram-positive cocci and bacilli. It 
is ineffective against most aerobic enteric gram-neg-
ative bacilli, but shows activity against some gram-
negative organisms in vitro, including Haemophilus 
influenzae, Neisseria meningitidis, and N. gonorrhoe-
ae  (Kapusnik-Uner  et  al.,  1996).  Erythromycin  is 
currently recommended for the treatment of syphi-
lis,  diphtheria,  and  Legionnaire's  disease  (Klein, 
1997). Also, this is the drug of choice for treating 
pregnant women with Chlamydia infections (Miller, 
2006). On the other hand, fungi, yeasts, and viruses 
are resistant to erythromycin (Sweetman, 2002). 
Side  effects  caused  by  erythromycin  are  rare. 
Derby  et  al.  (1993)  reported  a  case  of  choleas-
tatic hepatitis that developed after treatment with 
erythromycin. Erythromycin has in rare cases been 
reported to cause arrhythmia – most often in com-
bination with other drugs, for example verapamil 
(Goldschmidt et al., 2001) – liver dysfunction, and 
pancreatitis (Sweetman, 2002). Results obtained by 
Lanbeck  and  Paulsen  (1995)  suggest  dose-depen-
dent cytotoxicity of erythromycin for endothel cells 
after 24 h of exposure. According to the National 
Toxicology Program (1988), treatment with erythro-
mycin did not cause any neoplastic lesions.
When determining genotoxic agents, the forma-
tion of micronuclei (MN) is a common cytogenetic 
end point. Micronuclei are small extranuclear bod-
ies which occur as a result of chromosome damage 
(Mateuca et al., 2006; Zalacain et al., 2006) in divid-
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ing cells from an acentric chromosome, chromatic 
fragments,  or  whole  chromosomes  or  chromatids 
that  are  not  included  in  daughter  nuclei  in  telo-
phase (Fenech and Morley, 1985). Numerous studies 
showed that different factors can cause increase of 
spontaneous  micronucleus  (MN)  frequency  (Neri 
et al., 2005), as can chemical (Pedersen et al., 2006), 
physical (An and Kim, 2002), and biological (Suarez 
et al., 2007) agents. Moreover, the presence of MN 
in circulating lymphocytes is a relevant biomarker 
reflecting the biological effect of exposure to geno-
toxic  agents  (Milošević-Djordjević  et  al.,  2007). 
Since erythromycin is widely used in humans as a 
broad-spectrum antibiotic, the objective of the pres-
ent study was to investigate the effect of different 
concentrations of this antibiotic on MN frequency 
in human peripheral blood lymphocytes in vitro.
MATERIAL AND METHODS
Peripheral blood of three healthy donors (two 28-
year-old  females  and  a  40-year-old  man),  non-
smokers who had not been exposed to known envi-
ronmental mutagen agents, was used for determina-
tion  of  spontaneous  and  induced  MN  frequency. 
The  cytokinesis  block  micronucleus  test  (CBMN) 
was applied (Fenech, 2000).
Whole heparinized blood (0.5 ml) was cultured in 
5 ml of PBMax Karyotyping (Invitrogen, California, 
USA), the complete medium for lymphocyte culti-
vation. Double cell cultures were incubated at 37oC 
for 72 h. The tested substances were dissolved in the 
cultivation medium without serum and added to cell 
cultures 24 h after the beginning of incubation. The 
effect of erythromycin was tested in five different 
concentrations, 0.68 x 10-4, 1.36 x 10-4, 2.73 x 10-4, 
4.10 x 10-4, and 5.45 x 10-4 M. Cells treated with a 
known  mutagen,  mitomycin  C  (MMC,  Sigma,  St. 
Louis, MO, USA), in a concentration of 1.60 x 10-6 
M were used as the positive control.    
Forty-four hours after the beginning of incuba-
tion, cytochalasin B (Sigma, St. Louis, MO, USA) 
was added to the culture in a final concentration of 4 
μg/ml. The cultures were incubated for the next 28 h 
and then subjected to preparation. The preparation 
was standard. A hypotonic 0.56% KCl solution was 
used for this purpose, after which the cell suspen-
sion was fixed in methanol: glacial acetic acid (3: 
1) three times. Slides were stained with 2% Giemsa 
solution (Alfapanon, Novi Sad, Serbia).
Micronucleus  frequency  was  determined  by 
analyzing  1000  binucleated  (BN)  cells  per  culture 
according to the criteria for MN analysis described 
by Fenech (2000) and Kirsch-Volders et al. (2000). 
In  order  to  determine  the  cytotoxic  effect  of  the 
investigated concentrations of the medicament, the 
cytokinesis  block  proliferation  index  (CBPI)  was 
calculated using the formula: CBPI = [MI + 2MII + 
3(MIII + MIV)/500], where MI-MIV denotes the num-
ber of cells with 1-4 nuclei (Surralles et al., 1995). 
Statistical significance of the difference between 
average spontaneous and induced MN frequencies 
was determined using Student’s t-test. The correla-
tion between the investigated medicament concen-
trations and the percentage of BN cells in cultures 
treated with different doses of the medicament was 
determined  by  applying  Pearson  correlation  coef-
ficient. The variability of MN frequency was deter-
mined by analysis of variance (ANOVA).
RESULTS
Tables  1-4  present  the  results  of  MN  analyses  in 
peripheral  blood  lymphocytes  before  and  after  in 
vitro treatment with different concentrations of the 
antibiotic erythromycin. 
Table 1 shows individual values of MN frequen-
cies and CBPI in control and treated groups of cells 
obtained from three donors in good health. In con-
trol untreated cells, MN frequencies varied from 7 
to 8 MN per 1000 analyzed BN cells. Treatment with 
MMC in positive control cells caused a statistically 
significant increase of MN frequency (102 MN per 
1000 BN cells) in comparison to control untreated 
cells and all groups of cells treated with different 
concentrations  of  erythromycin  (p  <  0.001).  The 
values of CBPI ranged from 1.81 to 2.01 in untreated 
cultures, but dropped to 1.65 in the positive control. 
The values of CBPI in cultures treated with erythro-
mycin were in the range of 1.80-1.84. 
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Table 1. Frequency of MN in peripheral blood lymphocytes before and after in vitro treatment with different concentrations of eryth-
romycin (E). Abbreviations: BNMN - binucleated cells with MN, CBPI - cytokinesis-block proliferation index, C - control untreated 
cells, MMC - Mitomycin C.
Concentrations 
(M)
Frequency 
MN/1000
Analyzed 
BN BNMN Distribution of MN
1MN  2MN  3MN  4MN  5MN CPBI
Donor A
C - 8 1000 7       6          1          2.01
E1 0.68 x 10-4 7 1000 7       7           1.83
E2 1.36 x 10-4 9 1000 7       5          2 1.84
E3 2.73 x 10-4 7 1000 7       7 1.82
E4                 4.10 x 10-4 8 1000 7       6          1 1.84
E5 5.45 x 10-4 8 1000 7       6          1 1.82
Donor B
C - 7 1000 7       7 1.90
E1 0.68 x 10-4 8 1000 8       8 1.83
E2 1.36 x 10-4 7 1000 6       5          1 1.82
E3 2.73 x 10-4 10 1000 10     10 1.84
E4 4.10 x 10-4 7 1000 7       7 1.81
E5 5.45 x 10-4 7 1000 7       7 1.80
Donor C
C - 7 1000 7       7 1.81
E1 0.68 x 10-4 7 1000 6       5          1 1.80
E2 1.36 x 10-4 8 1000 7       6          1 1.81
E3 2.73 x 10-4 10 1000 8       6          2 1.81
E4 4.10 x 10-4 10 1000 8       6          2  1.84
E5 5.45 x 10-4 10 1000 9       8          1 1.84
Positive 
control 
(MMC)
1.60 x 10-6 102 1000 84      76          2         5                    1 1.65
CBPI in control and cell cultures treated with the 
tested concentrations of erythromycin. Comparison 
of control untreated and treated cells revealed that 
the tested concentrations of erythromycin did not 
influence the MN rate significantly (p > 0.05). The 
average frequency of MN per 1000 BN cells in con-
trol untreated cells was 7.33 ± 0.58. Analysis of the 
distribution  of  MN  revealed  that  the  investigated 
concentrations of erythromycin did not significantly 
change  the  number  of  BN  cells  containing  MN. 
Almost all tested concentrations of erythromycin, 
except  the  lowest  dose  (0.68  x  10-4  M),  slightly D. GRUJIČIĆ ET AL. 182
increased the number of MN in BN cells. The same 
table shows average CBPI values as well. All tested 
concentrations of erythromycin lowered the CBPI, 
but without statistical significance (p > 0.05). 
Table 3 presents the percentage of mononucle-
ated, binucleated, and polynucleated cells in treated 
cultures in relation to control untreated cells. In all 
treated  cell  cultures,  erythromycin  decreased  the 
percentage  of  polynucleated  cells.  A  statistically 
significant decrease was observed only in cultures 
treated with a 1.36 x 10-4 M concentration of erythro-
mycin (p < 0.05). The percentage of mononucleated 
and BN cells was slightly higher than in control cells, 
but without statistical significance. The Pearson cor-
relation coefficient showed no correlation between 
different  concentrations  of  erythromycin  and  the 
percentage of BN cells (R = 0.39, p > 0.05).
Application  of  ANOVA  to  MN  (Table  4)  did 
not reveal any statistically significant difference in 
comparison of between group (bg) vs. within group 
(wg) variance (F = 0.611, p > 0.05). The inter-indi-
vidual variance of MN was greater than the intra-
individual.  
Table 2. Average MN frequencies, MN distribution, and CBPI in peripheral blood lymphocytes after in vitro treatment with different 
concentrations of erythromycin (E) and in control cells (C). Abbreviations as in Table 1.
Treatment Concentrations
(M)
Average MN ± 
S.D./1000 BN 
cells
Total of ana-
lyzed 
BN cells
BNMN Distribution of MN
  1MN   2MN  3 MN
mean CBPI 
± S.D.
C
E1
E2
E3
E4
E5
-
0.68 x 10-4
1.36 x 10-4
2.73 x 10-4
4.10 x 10-4
5.45 x 10-4
7.33 ± 0.58
7.33 ± 0.58
8.00 ± 1.00
9.00 ± 1.73
8.33 ± 1.53
8.33 ± 1.53
3000
3000
3000
3000
3000
3000
21
21
20
25
22
23
20        1
20        1
16        4
23        2
19        3
21        2
1.91 ± 0.10
1.82 ± 0.02
1.82 ± 0.02
1.82 ± 0.02
1.83 ± 0.02
1.82 ± 0.02
Table 3. Presence of mononucleated (mono), binucleated (BN), and polynucleated (poly) lymphocytes after in vitro treatment with 
different concentrations of erythromycin (E) and in control cells (C). Abbreviations: % BN - percentage of BN cells, *Student’s t-test 
p < 0.05.
Treatment Concentrations (M) mono (%) BN (%) poly (%)
E1
E2
E3
E4
E5
0.68 x 10-4
1.36 x 10-4
2.73x 10-4
4.10 x 10-4
5.45 x 10-4
20.96
18.66
19.66
18.02
20.49
76.40
80.41
78.48
80.81
77.03
2.64
  0.93*
1.86
1.17
2.48
C 17.02 75.00 7.98
Table 4. Analysis of variance for MN before and after in vitro treatment with different concentrations of erythromycin.
Variance Sum of
squares df Mean square F Sig.
Between groups   4.400   4 1.100 0.611 0.664
Within groups 18.000 10 1.800
Total 22.400 14ERYTHROMYCIN AND MICRONUCLEI FREQUENCY IN HUMAN LYMPHOCYTES 183
DISCUSSION
Because  of  its  rapidness,  simplicity,  and  potential 
for  automation,  the  measurement  of  micronucle-
ated  cells  is  often  preferred  in  routine  genotoxic-
ity testing (Miller et al., 1997; Bonassi et al., 2007). 
The CBMN test became one of the most promising 
methodologies for assessing DNA damage because 
it affords the possibility detecting both chromosome 
and genome mutations in BN cells (Kirsch-Volders 
and Fenech, 2001). Apart from this characteristic, 
the relationship between MN frequency and genetic 
damage, as well as that between increase of MN fre-
quency and cancer risk, were the main arguments 
for using this test for evaluating the genotoxic effect 
of erythromycin in our study.
We  found  published  sources  which  treat  the 
effect of erythromycin on genetic material. However, 
in none of these studies was the MN test used as the 
biomarker of chromosomal damage. According to 
the National Toxicology Program (1988), erythro-
mycin did not produce an increase in the frequency 
of biomarkers such as sister chromatid exchanges 
(SCE)  or  chromosomal  aberrations  in  either  the 
presence  or  absence  of  metabolic  activation  (S9) 
after treatment of cultured Chinese hamster ovary 
cells. 
The results obtained on the average MN frequen-
cies in human peripheral blood lymphocytes after 
the end of treatment with different concentrations 
of erythromycin in vitro did not show a statistically 
significant increase (p > 0.05) in relation to MN val-
ues in control untreated cultures. As expected, only 
the positive control caused a significant increase of 
MN frequency (p < 0.001). 
The CBMN test is also used to detect effects on 
cell proliferation (Pastor et al., 2003) and cytotoxic-
ity  (Fenech,  2008)  by  following  changes  in  CBPI 
values (Laffon et al., 2001). This index shows the 
number of cell cycles through which treated cells 
have  passed  (Surralles  et  al.,  1995).  A  significant 
decrease of CBPI is associated with severe genomic 
damage which can stop further division of cells or 
activate the apoptosis mechanism (Kirsch-Volders 
and  Fenech,  2001).  Our  results  showed  that  all 
tested concentrations of erythromycin resulted in a 
decrease of CBPI, but without statistical significance 
(p > 0.05). 
Analysis of the percent of  binucleated cells in 
treated  cultures  showed  that  the  examined  con-
centrations of erythromycin induced a nonsignifi-
cant increase in the percentage of binucleated cells 
in  relation  to  control  untreated  cells  (p  >  0.05). 
Moreover,  at  all  tested  erythromycin  concentra-
tions, the percentage of mononucleated cells slightly 
increased.  Only  in  cultures  treated  with  a  1.36  x 
10-4 M erythromycin concentration did we obtain a 
statistically significant decrease in the percentage of 
polynucleated cells (p < 0.05).    
Previous investigations showed that MN distri-
bution in BN cells can indicate the level of genomic 
damage.  Тhus,  an  increase  of  MN  is  related  to 
chromosomal damage (Fenech and Morley, 1985), 
and there is positive correlation between these two 
biological endpoints (Joksić, 1999). Minozzo et al. 
(2004) demonstrated that cells with a greater num-
ber of MN suffered more genome damage. Analysis 
of  MN  distribution  showed  that  the  tested  con-
centrations of erythromycin, except for the lowest 
concentration (0.68 x 10-4
 M), slightly increase the 
number of MN in BN cells. In addition, the number 
of BN cells with MN slightly increases in cultures 
treated  with  the  three  highest  concentrations  of 
erythromycin (2.73 x 10-4, 4.10 x 10-4, and 5.45 x 
10-4 M).
Many authors point out that different life condi-
tions (such as work, living environment, and diet) 
can influence the baseline frequency of MN (Xue et 
al., 1992; Rekhadevi et al., 2009). The lymphocytes of 
patients before therapy showed an individual varia-
tion in MN/1000 BN cells of from 7 to 8, whereas 
after therapy it ranged from 7 to 10. By applying 
ANOVA  to  MN,  we  noticed  that  the  intra-indi-
vidual variance was lower than the inter-individual. 
Variability  in  the  induced  MN  frequency  may  be 
attributable  to  individual  reactivity  to  the  applied 
therapy. Numerous studies showed that in different 
persons subjected to treatment with the same dose 
of agents, the level of chromosomal damage was dif-
ferent, which was explained in terms of specificity D. GRUJIČIĆ ET AL. 184
of their reaction (Saritha and Ahuja, 1990; Grujičić 
et al., 2007).
Our results obtained using the CBMN test indi-
cate that the tested concentrations of erythromycin 
(0.68 x 10-4, 1.36 x 10-4, 2.73 x 10-4, 4.10 x 10-4, and 
5.45 x 10-4 M) did not affect micronucleus frequency 
in PHA-stimulated human lymphocytes. Finally, on 
the basis of these results and assuming that MNs can 
be used as biomarkers for substance genotoxicity, we 
conclude that this antibiotic in the tested concentra-
tions in vitro did not show any genotoxic effect in 
human peripheral blood lymphocytes.
Acknowledgment — The study was supported by the Ministry 
of Science of the Republic of Serbia (Grant No. 143008). 
REFERENCES
An, M. Y., and T. H. Kim (2002). Frequencies of micronuclei 
in peripheral lymphocytes in Korean populations after 
chronic low-dose radiation exposure. J. Vet. Sci. 3, 213-
218.
Bonassi,  S., Znaor, A., Ceppi, M., Lando, C., Chang, W. P., Hol-
land, N., Kirsch-Volders, M., Zeiger, E., Ban, S., Barale, 
R., Bigatti, M. P., Bolognesi, C., Cebulska-Wasilewska, A., 
Fabianova, E., Fucic, A., Hagmar, L., Joksić, G., Martelli, 
A., Migliore, L., Mirkova, E., Scarfi, M. R., Zijno, A., Norp-
pa, H., and M. Fenech (2007). An increased micronucleus 
frequency in peripheral blood lymphocytes predicts the 
risk of cancer in humans. Carcinogenesis 28, 625-631.
Czeizel, A. E., Rockenbauer, M., Sorensen, H. T., and J. Olsen 
(1999).  A  population-based  case-control  teratologic 
study of oral erythromycin treatment during pregnancy. 
Reprod. Toxicol. 13, 531-536.
Derby,  L.  E.,  Jick,  H.,  Henry,  D.  A.,  and  A.  D.  Dean  (1993). 
Erythromycin-associated  cholestatic  hepatitis.  Med.  J. 
Aust. 158, 600-602.
Fenech, M. (2000). The in vitro micronucleus technique. Mutat. 
Res. 455, 81-95.
Fenech, M. (2008). The micronucleus assay determination of 
chromosomal  level  DNA  damage.  Methods  Mol.  Biol. 
410, 185-216. 
Fenech, M., and A. A. Morley (1985). Measurement of micronu-
clei in lymphocytes. Mutat. Res. 147, 29-36.
Goldschmidt, N., Azaz-Livshits, T., Gotsman, Nir-Paz, R., Ben-
Yehuda,  A.,  and  M.  Muszkat  (2001).  Compound  car-
diac toxicity of oral erythromycin and verapamil. Ann. 
Pharmacother. 35, 1396-1399.
Grujičić,  D.,  Milošević-Đorđević,  O.,  Arsenijević,  S.,  and  D. 
Marinković (2007). The effect of combined therapy with 
ritodrine, erythromycin, and verapamil on the frequency 
of micronuclei in peripheral blood lymphocytes of preg-
nant women. Clin. Exp. Med. 7, 11-15.
Joksić,  G.  (1999).  Radiosensitivity  of  human  lymphocytes  in 
vitro  correlates  more  with  proliferative  ability  of  cells 
than with the incidence of radiation-induced damages of 
the genome. Neoplasma 46, 40-49.
Kapusnik-Uner, J. E., Sande, M. A., and H. F. Chambers (1996). 
Antimicrobial agents, In: The Pharmacological Basis of 
Therapeutics, 9 (Eds. J. G. Hardman and L. E. Limbrid), 
1123-1153. McGraw-Hill, New York.
Kirsch-Volders, M., and M. Fenech (2001). Inclusion of micro-
nuclei  in  non-divided  mononuclear  lymphocytes  and 
necrosis/apoptosis may provide a more comprehensive 
cytokinesis block micronucleus assay for biomonitoring 
purposes. Mutagenesis 16, 51-58.
Kirsch-Volders,  M.,  Sofuni,  T.,  Aaerdema,  M.,  Albertini,  S., 
Eastmond,  D.,  Fenech,  M.,  Ishidate,  M.  Jr,  Lorge,  E., 
Norppa, H., Surralles, J., von der Hude, W., and A. Wakata 
(2000). Reportfromtheinvitromicronucleusassaywork- Report from the in vitro micronucleus assay work-
ing group. Environ. Mol. Mutagen. 35, 167-172.
Klein,  J.  O.  (1997).  History  of  macrolide  use  in  pediatrics. 
Pediatr. Infect. Dis. J. 16, 427-431.
Laffon, B., Pasaro, E., and J. Mendez  (2001). Effects of styrene-
7,8-oxide  on  p53,  p21,  bcl-2,  and  bax  expression  in 
human lymphocyte cultures. Mutagenesis 16, 127-132. 
Lanbeck, P., and O. Paulsen (1995). Cytotoxic effects of four 
antibiotics on endothelial cells. Pharmacol. Toxicol. 77, 
365-370.
Mateuca,  R.,  Lombaert,  N.,  Aka,  P.  V.,  Decordier,  I.,  and  M. 
Kirsch-Volders    (2006).  Chromosomal  changes:  induc-
tion,  detection,  methods,  and  applicability  in  human 
biomonitoring. Biochimie 88, 1515-1531.
Miller, B., Albertini, S., Locher, F., Thybaud, V., and E. Lorge 
(1997). Comparative evaluation of the in vitro micro-
nucleus  test  and  the  in  vitro  chromosome  aberration 
test: industrial experience. Mutat. Res. 392 (1-2), 45-59, 
187-208.
Miller, K. E. (2006). Diagnosis and treatment of Chlamydia tra-
chomatis infection. Am. Fam. Physician 73, 1411-1416.
Milošević-Djordjević, O., Grujičić, D., Arsenijević, S., Brkić, M., 
Ugrinović, S., and D. Marinković (2007). Micronuclei in 
cord blood lymphocytes as biomarker of transplacental 
exposure to enviromental pollutants. Tohoku J. Exp. Med. 
213, 231-239.
Minozzo, R., Deimling, L. I., Gigante, L. P., and R. Santos-Mello 
(2004). Micronuclei in peripheral blood lymphocytes of 
workers exposed to lead. Mutat. Res. 565, 53-60.
National Toxicology Program (1988). NTP toxicology and car-
cinogenesis studies of erythromycin stearate (CAS No. 
643-22-1) in F344/N rats and B6C3F1 mice (feed stud-
ies). Natl. Toxicol. Program Tech. Rep. Ser. 338, 1-167.
Neri, M., Ceppi, M., Knudsen, L. E., Merlo, D. F., Barale, R., ERYTHROMYCIN AND MICRONUCLEI FREQUENCY IN HUMAN LYMPHOCYTES 185
Puntoni, R., and S. Bonassi (2005). Baseline micronuclei 
frequency in children: estimates from meta- and pooled 
analyses. Environ. Health Perspect. 113, 1226-1229.
Pastor, S., Creus, A., Parron, T., Cebulska-Wasilewska, A., Siffel, 
C., Piperakis, S., and R. Marcos (2003). Biomonitoring of 
four  European  populations  occupationally  exposed  to 
pesticides: use of micronuclei as biomarkers. Mutagenesis 
18, 249-258.
Pedersen, M., Vinzents, P., Petersen, J. H., Kleinjans, J. C., Plas, 
G.,  Kirsh-Volders,  M.,  Dostal,  M.,  Rossner,  P.,  Beskid, 
O., Sram, R. J., Merlo, D. F., and L. E. Knudsen (2006). 
Cytogenetic effects in children and mothers exposed to 
air pollution assessed by the frequency of micronuclei 
and fluorescence in situ hybridization (FISH): a family 
study in the Czech Republic. Mutat. Res. 608, 112-120.
Rekhadevi, P. V., Mahboob, M., Rahman, M. F., and P. Grover 
(2009). Genetic damage in wood dust-exposed workers. 
Mutagenesis 24, 59-65.
Saritha, T., and R. Z. Ahuja (1990). Inter-individual variation in 
chromosome aberration response to treatment with aphidi-
colin and folate deficiency. Med. Sci. Res. 18, 785-787.
Suarez, S., Sueiro, R. A., Araujo, M., Pardo, F., Menendez, M. D., 
Pardinas, M. C., and A. Alvarez (2007). Increased fre-
quency of micronuclei in peripheral blood lymphocytes 
of subjects infected with Helicobacter pylori. Mutat. Res. 
626, 162-170.
Surralles, J., Xamena, N., Creus, A., Catalan, J., Norppa, H., and 
R. Marcos (1995). Induction of micronuclei by five pyre-
throid insecticides in whole-blood and isolated human 
lymphocyte cultures. Mutat. Res. 341, 169-184.
Sweetman,  S.  C.  (2002).  The  Complete  Martindale  Drug 
Reference, 33, 201-204. Pharmaceutical Press, London. 
Xue, K. X., Wang, S., Ma, G. J., Zhou, P., Wu, P. Q., Zhang, R. F., 
Xu, Z., Chen, W. S., and Y. Q. Wang (1992). Micronucleus 
formation in peripheral-blood lymphocytes from smok-
ers and the influence of alcohol- and tea-drinking habits. 
Int. J. Cancer 50, 702-705.
Zalacain,  M.,  Sierrasesumaga,  L.,  Larrannaga,  C.,  and  A. 
Patinno-Garcia (2006). Effect of benzopyrene-7,8-diol-
9,10-epoxide (BPDE) in vitro and of maternal smoking 
in vivo on micronuclei frequencies in fetal cord blood. 
Pediatr. Res. 60, 180-184.
АНТИБИОТИК ЕРИТРОМИЦИН НЕ ПОВЕЋАВА ФРЕКВЕНЦУ МИКРОНУКЛЕУСА У 
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У овој студији је испитивана способност анти-
биотика еритромицина да индукује микронуклеу-
сну (MN) фреквенцу и цитокинезис блок пролифе-
рациони индекс (CBPI) у хуманим лимфоцитима 
периферне крви ин витро, помоћу цитокинезис-
блок  микронуклеусног  теста  (CBMH).  Ћелијске 
културе су третиране са пет различитих концен-
трација  еритромицина  од  0,68  x  10-4  do  5,45  x 
10-4 M. Позитивне контролне ћелије су третиране 
познатим мутагеном, митомицином C (MMC) у 
концентрацији 1,6 x 10-6 M. Све тестиране концен-
трације еритромицина нису статистички значајно 
мењале просечну MN фреквенцу и CBPI у PHA 
стимулисаним лимфоцитима (p > 0,05). 